# Study of TOP1630 for Dry Eye Syndrome

> **NCT03833388** · PHASE2,PHASE3 · COMPLETED · sponsor: **Topivert Pharma Ltd** · enrollment: 202 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** TOP1630 0.1% Ophthalmic Solution TID OU
- **DRUG:** Placebo to TOP1630 0.1% Ophthalmic Solution TID OU

## Key facts

- **NCT ID:** NCT03833388
- **Lead sponsor:** Topivert Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2019-05-14
- **Final completion:** 2019-05-14
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833388, "Study of TOP1630 for Dry Eye Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03833388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*